Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer
Paul A. Cohen(The University of Western Australia), Michael Friedländer(Prince of Wales Hospital), Penelope M. Webb(QIMR Berghofer Medical Research Institute), Val Gebski(The University of Sydney), Rachael L. Morton(University of Sydney), Jane Hill(Cancer Australia), Cyril Dixon(Cancer Australia), Patsy Yates(Queensland University of Technology), Rhonda Beach(Australia New Zealand Gynaecological Oncology Group), Andrew Dean, Philip Beale(The University of Sydney), Wanda Lawson(Australia New Zealand Gynaecological Oncology Group), Stephanie Jeffares(St John of God Subiaco Hospital), Rachel Campbell(South Eastern Health and Social Care Trust), Anne Mellon(John Hunter Hospital), Linda Mileshkin(Peter MacCallum Cancer Centre), Jim Codde(The University of Notre Dame Australia), Sue Hegarty(Cancer Australia), Tarek Meniawy(St John of God Subiaco Hospital), Angela Ives(The University of Western Australia), Alison H. Brand(The University of Sydney), Yeh Chen Lee(Royal Hospital for Women), Michelle McMullen(Sir Charles Gairdner Hospital), Phyllis Butow(Royal Prince Alfred Hospital), Sanela Bilic, Orla McNally(Royal Women's Hospital), Jeffrey C. Goh(The University of Queensland), Andreas Obermair(Royal Brisbane and Women's Hospital), I BLACK(St John of God Subiaco Hospital), Madeleine King(The University of Sydney)
Cited by 12
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k